AACR 2023 | The future of personalized, neoantigen cancer vaccines

Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York, NY, gives an overview of the promising future of cancer vaccines. The vaccine assessed in the Phase II Keynote-942 trial (NCT03897881), was the first one to provide clinical benefit in patients, and paves a way for adjuvant vaccines in a variety of PD-L1-postive cancers. A Phase III trial of a cancer vaccine in melanoma is additionally in the planning stages. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.